ACSS2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Cardiovascular Disorders
ACSS2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Cardiovascular Disorders
Acetyl-CoA synthetase 2 (ACSS2) is a protein that is involved in the metabolism of acetyl-CoA, a crucial molecule in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. This cycle is a central process for generating energy in the form of ATP from food molecules such as carbohydrates and fatty acids.
ACSS2 is a key enzyme in the TCA cycle, responsible for converting carbon dioxide and water to acetyl-CoA and carbon dioxide. It is a 2-dimensional protein that consists of an catalytic active site and a regulatory domain. The catalytic active site is located at the center of the protein and contains an active site for the substrate, carbon dioxide, to bind and activate the enzyme. The regulatory domain is located at the amino-terminal and docking region of the protein and plays a vital role in regulating the activity of the enzyme.
One of the significant features of ACSS2 is its role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. It has been shown to be involved in the regulation of cell proliferation, differentiation, and survival.
Additionally, ACSS2 has also been linked to the development and progression of several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Its role in these diseases has led to the idea of 鈥嬧?媢sing ACSS2 as a potential drug target or biomarker.
The use of ACSS2 as a drug target is based on the fact that ACSS2 is a validated drug target, and several compounds have been shown to inhibit its activity. These compounds have been shown to have a range of effects on cellular processes, including the inhibition of cell proliferation, migration and invasion.
Furthermore, ACSS2 has also been shown to be involved in the regulation of cellular processes that are crucial for the development and progression of several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Its role in these diseases has led to the idea of 鈥嬧?媢sing ACSS2 as a potential drug target or biomarker.
In conclusion, ACSS2 is a protein that plays a crucial role in the TCA cycle and has been shown to be involved in the regulation of cellular processes that are crucial for the development and progression of several diseases. Its potential as a drug target or biomarker makes it an attractive target for future research and development.
Protein Name: Acyl-CoA Synthetase Short Chain Family Member 2
Functions: Catalyzes the synthesis of acetyl-CoA from short-chain fatty acids (PubMed:10843999, PubMed:28003429). Acetate is the preferred substrate (PubMed:10843999, PubMed:28003429). Can also utilize propionate with a much lower affinity (By similarity)
More Common Targets
ACSS3 | ACTA1 | ACTA2 | ACTA2-AS1 | ACTB | ACTBL2 | ACTBP12 | ACTBP2 | ACTBP3 | ACTBP8 | ACTBP9 | ACTC1 | ACTE1P | ACTG1 | ACTG1P1 | ACTG1P10 | ACTG1P12 | ACTG1P17 | ACTG1P20 | ACTG1P22 | ACTG1P25 | ACTG1P4 | ACTG2 | Actin | Activating signal cointegrator 1 complex protein | Activin receptor type 2 (nonspecifed subtype) | ACTL10 | ACTL6A | ACTL6B | ACTL7A | ACTL7B | ACTL8 | ACTL9 | ACTMAP | ACTN1 | ACTN1-DT | ACTN2 | ACTN3 | ACTN4 | ACTR10 | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACTR3B | ACTR3BP2 | ACTR3BP5 | ACTR3BP6 | ACTR3C | ACTR5 | ACTR6 | ACTR8 | ACTRT1 | ACTRT2 | ACTRT3 | ACVR1 | ACVR1B | ACVR1C | ACVR2A | ACVR2B | ACVR2B-AS1 | ACVRL1 | ACY1 | ACY3 | Acyl-CoA dehydrogenase (ACAD) | Acyl-CoA Synthetase Short-Chain | ACYP1 | ACYP2 | ADA | ADA2 | ADA2A-containing complex (ATAC) | ADAD1 | ADAD2 | ADAL | ADAM10 | ADAM11 | ADAM12 | ADAM15 | ADAM17 | ADAM18 | ADAM19 | ADAM1A | ADAM1B | ADAM2 | ADAM20 | ADAM20P1 | ADAM21 | ADAM21P1 | ADAM22 | ADAM23 | ADAM28 | ADAM29 | ADAM30 | ADAM32 | ADAM33 | ADAM3A | ADAM5 | ADAM6 | ADAM7 | ADAM7-AS1